

What is claimed is:

1. A method of treatment of a disease state associated with Vascular Targeting comprising the administration of an effective amount of a Vascular Targeting Agent and an Anti-Hypertensive Agent to a mammal.
2. The method of claim 1, wherein said Vascular Targeting Agent is selected from the group consisting of a Combretastatin, a Combretastatin analog, and a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein said Vascular Targeting Agent is selected from the group consisting of Combretastatin A-4 Phosphate, Combretastatin A-1 Diphosphate, and a pharmaceutically acceptable salt thereof.
4. The method of claim 1, wherein said Anti-Hypertensive Agent is a Beta Blocker or a Vasodilator.
5. The method of claim 4, wherein said Beta Blocker is Propanolol or a derivative thereof.
6. The method of claim 4, wherein said Vasodilator is Sodium Nitroprusside or a derivative thereof.
7. A pharmaceutical composition, comprising:
  - a) a Vascular Targeting Agent or a pharmaceutically acceptable salt or solvate thereof;
  - b) an Anti-Hypertensive Agent or a pharmaceutically acceptable salt or solvate thereof; and optionally
  - c) a pharmaceutically acceptable carrier or diluent.
8. A kit comprising:

- a) a Vascular Targeting Agent or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof;
  - b) an Anti-Hypertensive Agent or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof; and
  - c) a container means for containing said Agents.
9. A method of manufacturing a medicament for the treatment of a disease state associated with Vascular Targeting in a mammal comprising combining a Vascular Targeting Agent and an Anti-Hypertensive Agent in a kit.
10. The method of claim 9, wherein said Vascular Targeting Agent is selected from the group consisting of a Combretastatin, a Combretastatin analog, and a pharmaceutically acceptable salt thereof.
11. The method of claim 9, wherein said Vascular Targeting Agent is selected from the group consisting of Combretastatin A-4 Phosphate, Combretastatin A-1 Diphosphate, and a pharmaceutically acceptable salt thereof.
12. The method of claim 9, wherein said Anti-Hypertensive Agent is a Beta Blocker or a Vasodilator.
13. The method of claim 12, wherein said Beta Blocker is Propanolol or a derivative thereof.
14. The method of claim 12, wherein said Vasodilator is Sodium Nitroprusside or a derivative thereof.